Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers. Issue 2 (1st February 2020)

• Record Type: Journal Article
• Authors: Luo, Ming; Li, Fu; Su, Ka; Yuan, Huiming; Zeng, Jian
• Is Part Of: Cancer biology & therapy. Volume 21:Issue 2(2020)
• Page Start: 108
• Page End: 112
• Publication Date: 2020-02-01
• Subjects: Breast cancer -- NCCN guidelines -- St. Gallen International Consensus -- estrogen receptor -- progesterone receptor -- HER2 -- Ki67; 616.99406
• DOI: 10.1080/15384047.2019.1669994
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: This study aimed to evaluate the impacts of 21-gene recurrence score (RS) and St. Gallen International Expert Consensus on treatment decision and prognosis of patients with invasive breast cancer. We retrospectively analyzed the therapy protocol and outcome of 134 cases based on age, body mass index (BMI), menopause, pathological types, tumor-node-metastasis (TNM) stages, percentage of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2), Ki-67, molecular subtype, and tumor biomarkers. RS was calculated based on 21-gene assay following traditional (old RS cutoff) and updated (new RS cutoff) National Comprehensive Cancer Network (NCCN) guideline. In addition, we also compared treatment protocol of NCCN guidelines with St. Gallen International Expert Consensus. The results showed that BMI, PR, Ki-67, and molecular subtype are critical for the evaluation of risk factors. Based on the new cutoff, low, middle, and high RS were 18%, 66%, and 16%, respectively. In contrast, based on the old cutoff, low, middle, and high RS were 60%, 29%, and 11%, respectively. The agreement rate of NCCN guidelines and St. Gallen International Expert Consensus for adjuvant treatment was 50. However, there is minimal agreement (0.151, 0.071) in kappa coefficient of old and new cutoff. This study revealed that the combination of NCCN guidelines and St. Gallen International Expert Consensus might improve the benefits of adjuvant treatment in patients with early invasive breast cancer.